NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative immunomedicines to treat cancer. The company focuses on patients who do not respond to current therapies, whose cancer progresses despite treatment, and those with cancer types not adequately addressed by available therapies. NextCure leverages its proprietary FIND-IOTM technology to identify novel targets and develop therapies that modulate immune responses within the tumor microenvironment, aiming to restore anti-tumor activity and address significant unmet medical needs.
Industries
Nr. of Employees
medium (51-250)
NextCure, Inc.
Beltsville, Maryland, United States, North America
Products
Antibody-drug conjugate targeting B7-H4 (pre-IND)
Antibody-drug conjugate designed to bind tumor-expressed B7-H4 with reduced off-target toxicity and demonstrated antitumor activity in animal models; advancing toward IND with ongoing GMP manufacturing and GLP toxicology studies.
LAIR-1 blocking immunomodulator for tumor ECM remodeling
Biologic designed to block LAIR-1–mediated immune suppression and remodel collagen in the extracellular matrix to enhance T cell tumor infiltration; evaluated in nonclinical models and early-phase combination clinical studies with PD-1 pathway inhibitors.
Monoclonal antibody targeting LAIR-1 for hematologic malignancy
Monoclonal antibody that binds LAIR-1 to induce killing of AML blast cells and leukemic stem cells while sparing normal hematopoietic cells; evaluated in preclinical models and in Phase I dose-escalation study.
Monoclonal antibody targeting Siglec‑15 for bone disorders
Antibody designed to inhibit osteoclast activity to prevent bone loss and promote bone formation; development targets rare bone diseases and disorders such as osteogenesis imperfecta, non-union fractures and osteoarthritis.
Monoclonal antibody targeting APOE4 for neurodegenerative disease
Antibody candidate against APOE4 intended to reduce amyloid plaque burden, suppress neuroinflammation and improve cerebral blood flow for treatment of Alzheimer’s disease risk associated with APOE4.
Antibody-drug conjugate targeting B7-H4 (pre-IND)
Antibody-drug conjugate designed to bind tumor-expressed B7-H4 with reduced off-target toxicity and demonstrated antitumor activity in animal models; advancing toward IND with ongoing GMP manufacturing and GLP toxicology studies.
LAIR-1 blocking immunomodulator for tumor ECM remodeling
Biologic designed to block LAIR-1–mediated immune suppression and remodel collagen in the extracellular matrix to enhance T cell tumor infiltration; evaluated in nonclinical models and early-phase combination clinical studies with PD-1 pathway inhibitors.
Monoclonal antibody targeting LAIR-1 for hematologic malignancy
Monoclonal antibody that binds LAIR-1 to induce killing of AML blast cells and leukemic stem cells while sparing normal hematopoietic cells; evaluated in preclinical models and in Phase I dose-escalation study.
Monoclonal antibody targeting Siglec‑15 for bone disorders
Antibody designed to inhibit osteoclast activity to prevent bone loss and promote bone formation; development targets rare bone diseases and disorders such as osteogenesis imperfecta, non-union fractures and osteoarthritis.
Monoclonal antibody targeting APOE4 for neurodegenerative disease
Antibody candidate against APOE4 intended to reduce amyloid plaque burden, suppress neuroinflammation and improve cerebral blood flow for treatment of Alzheimer’s disease risk associated with APOE4.
Services
End-to-end biologics development (research to IND)
Integrated development services from gene cloning and cell line development through process development, formulation, analytical characterization and IND-enabling studies to prepare clinical material and regulatory submissions.
GMP manufacturing and GLP toxicology support
Provision or coordination of GMP-compliant manufacturing for clinical supplies and execution/management of GLP toxicology studies to support regulatory filings.
Translational assay and biomarker development
Development of assays for patient selection, biomarker analysis, and clinical trial monitoring to support translational and clinical programs.
Strategic partnering and in‑licensing
Partnering programs including licensing of late-stage clinical assets and collaboration on therapeutic candidates and technologies.
Early-phase clinical development and combination studies
Design and conduct of Phase I clinical trials, including combination studies with other immunotherapies and collection of clinical activity data.
End-to-end biologics development (research to IND)
Integrated development services from gene cloning and cell line development through process development, formulation, analytical characterization and IND-enabling studies to prepare clinical material and regulatory submissions.
GMP manufacturing and GLP toxicology support
Provision or coordination of GMP-compliant manufacturing for clinical supplies and execution/management of GLP toxicology studies to support regulatory filings.
Translational assay and biomarker development
Development of assays for patient selection, biomarker analysis, and clinical trial monitoring to support translational and clinical programs.
Strategic partnering and in‑licensing
Partnering programs including licensing of late-stage clinical assets and collaboration on therapeutic candidates and technologies.
Early-phase clinical development and combination studies
Design and conduct of Phase I clinical trials, including combination studies with other immunotherapies and collection of clinical activity data.
Expertise Areas
- Immuno-oncology target discovery
- Therapeutic monoclonal antibody development
- Antibody-drug conjugate (ADC) development
- Translational preclinical development and IND enabling studies
Key Technologies
- Functional, cell-based immune pathway screening
- Primary human immune cell assays
- Monoclonal antibody discovery
- Antibody-drug conjugate design